Search Login Register

promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein Summary

Description: selectively expressed in acute promyelocytic leukemia cells; recognized by T lymphocytes; amino acid sequence given in first source; product of a functionally altered retinoic acid receptor alpha gene

Also Known As: PML-RARalpha; PML-RARalpha protein

Networked: 264 relevant articles (22 outcomes, 16 trials/studies) for this Bio-Agent

Key Diseases for which promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein is Relevant

  1. Acute Promyelocytic Leukemia : 16 outcomes 13 studies in 179 results
  2. Leukemia : 8 outcomes 3 studies in 83 results
  3. Acute Myeloid Leukemia (Acute Myelogenous Leukemia) : 2 outcomes in 23 results
  4. Residual Neoplasm : 1 outcome 2 studies in 15 results
  5. Hematologic Neoplasms (Hematological Malignancy) : 1 outcome in 1 result
Show All >>

Drugs Related to promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

  1. Tretinoin (Retinoic Acid)
  2. arsenic trioxide (Trisenox)
  3. retinoic acid receptor alpha
  4. Messenger RNA (mRNA)
  5. Aligeron (AS 2)
  6. Valproic Acid (Valproate, Semisodium)
  7. RNA-Directed DNA Polymerase (Reverse Transcriptase)
  8. Arsenic
  9. Histone Deacetylase Inhibitors
  10. RNA (Ribonucleic Acid)
Show All >>

Therapies Related to promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

  1. Drug Therapy (Chemotherapy)
  2. Transplants (Transplant)
  3. Stem Cell Transplantation
  4. Salvage Therapy
  5. Bone Marrow Transplantation (Transplantation, Bone Marrow)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.